摘要
目的：了解强力宁的抗纤维化作用。方法：应用放免法和酶标法对所有研究对象进行前胶原Ⅲ肽（ＰⅢＰ）和透明质酸（ＨＡ）及Ⅳ胶原的检测，同时应用强力宁对部分慢性肝炎患者进行治疗，并随访８周。结果：慢性肝炎患者的ＰⅢＰ、ＨＡ及Ⅳ型胶原水平明显高于正常对照组（Ｐ＜０．０１）；肝组织纤维化程度与ＰⅢＰ、ＨＡ及Ⅳ型胶原水平有关系，以Ｓ３和Ｓ４期最高；强力宁治疗第６周时血清ＰⅢＰ水平下降（Ｐ＜０．０５），８周时，ＰⅢＰ、ＨＡ和Ⅳ型胶原水平均较治疗前低（Ｐ＜０．０５）。结论：肝纤维化时，血清ＰⅢＰ、ＨＡ及Ⅳ型胶原明显升高，３个指标的结合应用可作为肝纤维化早期诊断指标，强力宁有抑制肝纤维化的作用。
Objective: To investigate antifibrosis of Potenlin in chronic hepatitis. Methods: Serum levels of type Ⅲ procollagen peptide (PⅢP), hyaluronic acid (HA) and type Ⅳ collagen were measured by radioimmunoassay and ELISA in patients with CH and normal controls. More than half patients with CH were treated with Potenlin for eight weeks to evaluate its antifibrotic effect. Results: Concentration of P Ⅲ P. HA and type Ⅳ collagen were much higher than those in normal controls (P<0. 01). Relationship was found between degree of fibrosis in liver tissue and serum level of P Ⅲ P, HA and type Ⅳ collagen with highest level in S3 and S4 stage. Serum level of PⅢP at sixth week and HA or typeⅣ collagen at eighth week after Potenlin treatment were significently decreased (P < 0. 05), compared to pre - treatment and controls of same periods. Conclusion: Serum level of P ⅢP, HA and type Ⅳ collagen were significently increased (P < 0. 01) and combined examination could be helpful to early diagnosis of hepatic fibrosis. Potenlin was somewhat effective in treating hepatic fibrosis.
